Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil Citrate for Cerebrovascular Dysfunction in Chronic TBI
NCT05782244Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP-001 in traumatic brain injury (TBI) (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Delta Cerebrovascular Reactivity. Started Jul 2024; status: recruiting.
02
Drugs
ASP-001
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05782244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782244.